This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Ropidoxuridine

Spectrum Pharmaceuticals, Inc.

Drug Names(s): IPdR

Description: Ropidoxuridine is an orally available, thymidine analogue and prodrug for iododeoxyuridine (IUdR).

Deal Structure: Ropidoxuridine was developed by Talon.

Talon and Spectrum
In July 2013, Spectrum announced that the company entered into an agreement to acquire Talon Therapeutics. In connection with the closing of the acquisition, Spectrum will pay Talon stockholders an aggregate upfront cash consideration of approximately $11.3 million and will issue 3 million shares of its common stock in exchange for the cancellation of all of the outstanding indebtedness under Talon's credit facility. Talon stockholders will also receive contingent value rights (CVRs) in an aggregate of up to $195 million in future cash payments from Spectrum upon the achievement of certain one-time sales-based milestones for Marqibo and an approval-based milestone for Menadione Topical Lotion. There can be no assurance as to the actual value, if any, of a CVR. The CVRs will not be publicly traded. The per share purchase price for each outstanding share of Company common stock payable at closing to the...See full deal structure in Biomedtracker


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug